This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CytRx’s Tamibarotene Continues To Protect Touring Professional Musician And Former NBA Player Ray Johnston From Leukemia

For more than two years, former Dallas Maverick basketball player Ray Johnston has been cancer-free. His advanced, highly aggressive acute promyelocytic leukemia (APL) was totally eradicated in 2010, just four months after beginning treatment with CytRx Corporation’s (NASDAQ:CYTR) cancer drug candidate tamibarotene. Since then, Mr. Johnston has continued taking tamibarotene tablets every other month to guard against a relapse.

“Every day without leukemia is a celebration,” said Mr. Johnston, who leads a very active lifestyle with the band he formed following his diagnosis. The Ray Johnston Band is booking about 100 shows across the U.S. this year with a sound described by Johnston as halfway between Zac Brown and Dave Matthews.

Tamibarotene was developed to be more potent and avoid some of the toxic side effects of all trans-retinoic acid (ATRA)—the current first-line treatment for APL. CytRx is currently testing tamibarotene as a third-line treatment for this form of leukemia.

CytRx also is evaluating tamibarotene in combination with other chemotherapeutic agents in a late-stage, global Phase 2b clinical trial as a first-line treatment for non-small cell lung cancer (NSCLC). Positive signs of efficacy in patients with APL such as Ray Johnson further bolster the case for tamibarotene’s drug activity, providing hope for its success in patients with lung cancer, which is responsible for more deaths than breast, prostate and ovarian cancers combined. Last month an independent group of oncologists and biostatistitions who comprise the Data Safety Monitoring Board for this global trial recommended moving forward with clinical testing following an interim review of safety data. The Company expects to report trial results next year.

Mr. Johnston was diagnosed with APL at the age of 24, ending his brief career as a professional basketball player with the Dallas Mavericks. For the following six years, he was treated with multiple therapies for APL approved by the U.S. Food and Drug Administration (FDA), including ATRA, as well as anthracycline chemotherapy, Mylotarg® and arsenic trioxide (ATO). He even underwent a blood stem cell transplant. Although his leukemia went into remission several times, it always came back with a vengeance. In fact, a PET scan performed just prior to his treatment with tamibarotene showed more than 30 tumors throughout his body.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs